News

The regulator has approved the therapy as a potential new standard of care to treat Pompe disease, a rare, progressive and severe muscle disorder. Individuals with this disease

Rinvoq, which is discovered and developed by AbbVie scientists, is a selective JAK inhibitor that is being studied in many immune-mediated inflammatory diseases. The regulator has recommended the

A fully human biologic, Cosentyx has been developed to directly inhibit interleukin-17A (IL-17A), a cytokine. The regulatory approval is granted for the use of the therapy, either alone

The vaccine candidate seeks to prevent anthrax in people after suspected or confirmed exposure to Bacillus anthracis. AV7909 is being assessed in adult persons between 18 and 65

The combination therapy is indicated to treat unresectable or metastatic solid tumours with the BRAF V600E mutation in adult and paediatric patients aged six years and above whose

EP0031 is a potent next generation selective RET inhibitor (SRI) with broad activity against common RET fusions and mutations, like solvent front resistance mutations. It is jointly developed

Imcivree is a melanocortin-4 receptor (MC4R) agonist which is indicated for chronic weight management in adult and paediatric patients aged six years and above with monogenic or syndromic

VBI-1901 is a new cancer vaccine immunotherapeutic candidate that uses cytomegalovirus (CMV) as a foreign viral antigen approach to treat cancer by expressing two highly immunogenic CMV antigens,

Atogepant is an oral calcitonin gene-related peptide [CGRP] receptor antagonist (gepant) which has been specifically developed as the preventive migraine treatment. In September last year, the drug received